panorama™ prenatal screen

highly accurate, comprehensive results you can trust

Natera is dedicated to providing you and your patients with the best prenatal screening test available.

COMPARE THE DIFFERENCE:

Panorama™ has 2X higher positive predictive value (PPV) compared to Verifi® in a low risk population.[1,2]

PPV is the probability that pregnancies that screen as positive or high-risk are truly affected by the condition. Higher PPV means fewer unnecessary CVS and amnios.

POSITIVE PREDICTIVE VALUE: T21 AND T18 COMBINED



Note: the aneuploidy call rates were as follows:
Panorama - low risk patients: 0.7%
Panorama - all patients: 1.3%
Verifi: 0.8%

REDUCING DISCORDANCE

- **Vanishing Twin**
  Only Panorama can detect a vanishing twin, which contributes to >15% of discordant results with Verifi.[3]

- **Maternal Chromosomal Abnormalities**
  Only Panorama can recognize maternal mosaicism, which is associated with up to 8.6% of false positives when screening sex chromosomes with shotgun sequencing.[4]

Panorama's Extended Microdeletion panel is now available to order with Panorama's aneuploidy panel.

- Panorama's Microdeletion panel has been validated with more samples than that of Verifi.

RESULTS FROM VALIDATION STUDIES

Disorder	Incidence (1:n)	Panorama™ sensitivity[5]	Verifi® sensitivity[6]
22q11.2	2,000	**95.7% (45/47)**	87.5% (7/8)
Prader-Willi	10,000	**93.8% (15/16)**	0% (0/1)
Angelman	12,000	**95.5% (21/22)**	0% (0/1)
1p36	5,000	**100% (1/1)**	N/A (0/0)
Cri-du-chat	20,000	**100% (24/24)**	100% (2/2)

CLIA and ISO 13485 certified, and CAP accredited

panorama™ prenatal screen

highly accurate, comprehensive results you can trust

Only Panorama has 100% accuracy in fetal sex determination in validation studies.

With Verifi, as many as 1 in 100 cases may report incorrect gender.[7]

ERROR RATES IN FETAL SEX DETERMINATION: RESULTS FROM VALIDATION STUDIES



Note: Fetal sex determined by presence of Y, where Monosomy X is female.

Personalized results for easier patient counseling.

- Panorama results are reported as a personalized risk score, along with fetal fraction.
- In case of a high risk result you will know the likelihood of the fetus truly being affected and will be able to confirm via CVS or amniocentesis.
- Verifi reports results as "aneuploidy detected," "aneuploidy suspected" or "aneuploidy not detected." Fetal fraction is not reported. There is no way to know the likelihood of the fetus actually being affected.

Genetic counseling services to help provide clarity and explain options.

- You now have access to Natera's team of Certified Genetic Counselors to help answer your questions. They can be reached at niptgc@natera.com or by calling +1-650-249-9090.

Panorama is the only NIPT that distinguishes between fetal and maternal DNA to determine fetal aneuploidy status.

- Leveraging SNP-based sequencing and powered by Natera's proprietary NATUS™ (Next-Generation Aneuploidy Test Using SNPs) algorithm, Panorama delivers the most accurate results for the most common and severe aneuploidies and microdeletions.

1. Dar et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based non-invasive prenatal aneuploidy testing. Am J Ob & Gyn, 2014 (in press).
2. Bianchi et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl Journal of Medicine, 2014 Feb; 370:799-808.
3. Futch et al. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diag 2013; 33(6):569-74.
4. Wang Y et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clinical Chemistry 2014; 60(1):251-9.
5. Wapner R et al. Highly accurate single-nucleotide polymorphism-based non-invasive prenatal detection of microdeletion syndromes. Manuscript under review.
6. Verifi marketing communication.
7. www.verifitest.com
8. Mazloom A et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn. 2013; 33(6):591-7.
9. Nicolaides KH et al. Assessment of fetal sex aneuploidy using directed cell-free DNA analysis. Fetal Diagn Ther, Epub 2013 Dec 11.
10. Nicolaides KH et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X and Y. Prenat Diagn 2013; 33(6):575-9.
11. Samango-Sprouse et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diag 2013; 33:1-7.

natera™ Conceive. Deliver.

Panorama: part of the Natera family of products

panorama™ prenatal screen | horizon™ carrier screen | spectrum™ preimplantation genetics (PGS/PGD) | anora™ miscarriage test (POC)

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | +1-650-249-9090 | Fax 1-650-730-2272

CAP accredited, ISO 13485 and CLIA certified

PAN-VERIFICOMP-V2(6/25/14)INTRNTL